---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-010330"
form_type: "8-K"
ticker: "PROK"
cik: "0001850270"
company_name: "PROKIDNEY CORP."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T13:38:51.268274+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ProKidney reports Q4 net loss of $24.6M; cash $490.3M; Phase 3 trials advancing

## Summary
- Cash and cash equivalents $490.3M as of Dec 31, 2022, vs $20.6M year-end 2021.
- R&D expense $20.9M in Q4 2022, up from $10.7M in Q4 2021 due to clinical trial costs and hiring.
- Net loss before noncontrolling interest $24.6M for Q4 2022, compared to $13.7M for Q4 2021.
- Proact1 Phase 3 trial enrolling; interim data expected end of 2024; proact2 trial progressing toward initiation.
- REACT received RMAT designation; EMA provided favorable scientific advice for Phase 3 program.

## SEC filing metadata
- accession: 0000950170-23-010330
- form_type: 8-K
- ticker: PROK
- cik: 0001850270
- company_name: PROKIDNEY CORP.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/0000950170-23-010330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/prok-20230328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-010330
- JSON: https://secwatch.observer/filing/0000950170-23-010330.json
- Plain text: https://secwatch.observer/filing/0000950170-23-010330.txt

## Key facts
- Earnings Releases
  PROKIDNEY CORP. reported the fourth quarter ended December 31, 2022 results: net income $24.6 million.
  - Period: the fourth quarter ended December 31, 2022
  - Net income: $24.6 million
  - Result: reported results
  source text: Net loss before noncontrolling interest was $24.6 million and $13.7 million for the three months ended December 31, 2022, and 2021, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/0000950170-23-010330-index.htm
- Earnings Releases
  PROKIDNEY CORP. reported financial results for the fiscal year ended December 31, 2022.
  - Period: the fiscal year ended December 31, 2022
  - Result: reported results
  source text: On March 28, 2023, ProKidney Corp. issued a press release to announce its financial results for the fourth quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1850270/000095017023010330/0000950170-23-010330-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.